The HEPATIQ test is ordered by clinical physicians such as hepatologists, gastroenterologists, oncologists, interventional radiologists, liver surgeons, and internists. The patient’s liver and spleen are imaged in a hospital radiology/nuclear medicine department or in an independent imaging center using a SPECT scanner.
The fed patient is injected with a standard low dose (about 5 mCi) short-acting Technicium-99m sulfur colloid solution. The patient is scanned for about 20 minutes and planar and SPECT images acquired. The images are analyzed by the HEPATIQ software and a report prepared for review by the nuclear medicine physician. The reviewing physician’s dictation together with the HEPATIQ report is distributed to the ordering clinical physician.
Nuclear medicine scans are safe, painless and cost-effective techniques that help diagnose medical conditions. They are unique because they provide information about both structure and function of the organ that would not otherwise be available. They often identify problems and abnormalities early in a disease process long before they show up on other diagnostic tests. Nuclear medicine differs from an x-ray, ultrasound or other diagnostic test because it determines the presence of disease based on biological changes rather than changes in anatomy.
The HEPATIQ software is cleared for sale by the U.S.A. Food and Drug Administration.
The liver SPECT scan is reimbursed by insurance under CPT 78803 and can boost nuclear medicine revenues.
no capital investment
HEPATIQ is pure software and uses existing equipment, radioisotope, infrastructure and staff. No capital investment is needed and only a usage fee is charged.